Product details

This is the first of a two-case series. This case examines the decision by the UK subsidiary of Pharma (a Swiss pharmaceutical company) to develop a new technology for transmitting drugs through the skin, despite the absence of support from the parent company's R&D labs. The issue facing the managing director of the UK subsidiary is whether to continue with the project in the face of resistance from HQ, or stop.